Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive versus maintenance therapy for subclinical synovitis in rheumatoid arthritis patients in remission or low disease activity
ChiCTR2000029279Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Aug 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of umbilical cord-derived mesenchymal stem cells (Alliancells) in rheumatoid arthritis (RA) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Joint ultrasound, C-reactive protein and 3 more. Started Aug 2017; status: completed.
02
Drugs
umbilical cord-derived mesenchymal stem cells (Alliancells)
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000029279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029279.